MoonLake Immunotherapeutics has reported 52-week Phase 3 results showing that 67.2% of sonelokimab-treated adults with moderate-to-severe hidradenitis suppurativa achieved at least a 75% reduction in inflammatory lesions without worsening abscesses or draining tunnels. The Nasdaq-listed biotechnology company plans to submit a United States biologics licence application by the end of September 2026, setting up a regulatory test for a programme that previously triggered one of the sector’s sharpest clinical-data sell-offs.
Why the 52-week VELA results matter more than another incremental clinical update
The latest results provide the first complete one-year view across the VELA-1 and VELA-2 registrational studies. MoonLake is no longer asking investors to value sonelokimab primarily through an early placebo-controlled endpoint. The company is presenting sustained disease control, complete lesion responses, inflammatory remission, pain reduction and quality-of-life improvements across nearly 400 continuously treated patients.
Across the two trials, 67.2% of sonelokimab-treated patients achieved HiSCR75 at week 52, while 33.1% achieved HiSCR100, indicating complete resolution of abscesses and inflammatory nodules without an increase in draining tunnels. Approximately 26% achieved IHS4-100, a stricter measure requiring complete elimination of abscesses, inflammatory nodules and draining tunnels.
Those higher-threshold outcomes are important because hidradenitis suppurativa is not merely a condition involving temporary skin lesions. Persistent inflammation can create tunnels beneath the skin, irreversible scarring, chronic drainage, pain and substantial psychological burden. A treatment capable of moving patients toward deep inflammatory remission may have greater long-term value than one producing only partial lesion reduction.
The dataset also showed consistency between VELA-1 and VELA-2. HiSCR75 reached 68.3% and 66% in the respective trials, while HiSCR100 reached 31.2% and 35.1%. Similar performance reduces concern that the pooled outcome was driven by one unusually successful study.
The result does not erase the mixed perception created at week 16. One of the two VELA trials narrowly missed statistical significance under its primary composite analysis because of a higher-than-expected placebo response. The latest data instead suggest that sonelokimab’s differentiation may become clearer with longer treatment.
How the week-52 data change the interpretation of the earlier Phase 3 disappointment
MoonLake shares collapsed after the initial VELA results in September 2025 because investors had expected two unambiguous Phase 3 successes and a larger separation from placebo. VELA-1 met the primary endpoint under both prespecified analytical strategies, while VELA-2 missed under the primary composite approach with a p-value of 0.053.
That outcome created a difficult narrative. The programme appeared biologically active and clinically relevant, but the result fell short of the clean statistical profile required to support a confident best-in-class argument. The market rapidly reduced the probability it assigned to approval, commercial leadership and strategic interest from larger pharmaceutical companies.
The 52-week results provide a different view. Responses continued to deepen after week 16 rather than plateauing or declining. Patients who crossed from placebo to sonelokimab also experienced a rapid increase in response, with HiSCR75 improving by approximately 20 percentage points after only four weeks of active treatment.
By the end of the programme, placebo crossover patients reached response levels similar to those seen in patients with comparable continuous sonelokimab exposure. This supports the interpretation that the therapy rather than study participation or natural disease fluctuation produced the later improvement.
The regulatory argument is therefore broader than one borderline p-value. MoonLake can present two identically designed studies, a positive pooled programme, durable one-year responses, clinically meaningful patient-reported outcomes and a consistent mechanistic effect after placebo crossover.
The remaining vulnerability is that regulators do not simply average away an unsuccessful primary analysis. MoonLake must demonstrate that the full evidence package is sufficiently robust and that the statistical complexities do not conceal an unstable or inflated treatment effect.
Can sonelokimab establish a meaningful advantage over approved IL-17 competitors?
Sonelokimab inhibits both interleukin-17A and interleukin-17F, inflammatory signals involved in hidradenitis suppurativa and several related immune-mediated diseases. This places it in direct competition with established IL-17 therapies, particularly bimekizumab and secukinumab.
Bimekizumab also blocks interleukin-17A and interleukin-17F and is approved for moderate-to-severe hidradenitis suppurativa in adults. Secukinumab inhibits interleukin-17A and is approved for adults and adolescents aged 12 years and older.
MoonLake argues that the smaller molecular structure of sonelokimab may improve penetration into inflamed tissue. The molecule also includes an albumin-binding domain intended to increase concentration within inflammatory oedema, potentially delivering more active drug where lesions and tunnels are developing.
The week-52 results appear numerically favourable compared with published outcomes from competing Phase 3 programmes. MoonLake has highlighted higher observed response rates across HiSCR75, HiSCR100 and inflammatory-remission measures.
Cross-trial comparison remains an imperfect basis for commercial claims. Studies differ in patient severity, previous biologic exposure, handling of treatment discontinuations, missing data, definitions, geographical mix and statistical analysis. An observed week-52 percentage from one trial cannot be treated as proof of superiority over a percentage generated through a different study design.
The clearest differentiation may instead involve the combination of deep response, pain relief, quality-of-life improvement and once-every-four-weeks maintenance dosing. Sonelokimab does not need to be superior on every measure. It needs a profile strong enough to convince dermatologists and payers that it offers a meaningful reason to select or switch treatment.
Why pain and quality-of-life improvements could influence real-world adoption
Clinical trial headlines in hidradenitis suppurativa often focus on lesion counts because these provide standardised regulatory endpoints. Patients may judge treatment success through a broader set of outcomes, including pain, drainage, smell, mobility, sleep, clothing choices, intimacy and the ability to work.
Approximately 46.5% of evaluable sonelokimab-treated patients achieved at least a three-point reduction in their worst skin-pain score. The mean hidradenitis suppurativa-specific quality-of-life score improved by approximately 15 points, moving the average patient from severe impairment toward mild impairment.
These findings strengthen the clinical value argument because lesion reduction that does not change daily functioning may have limited relevance to patients living with chronic painful disease. Pain improvement can affect sleep, movement, employment and reliance on analgesic medication.
Quality-of-life results may also influence physician perception when several biologics offer broadly similar mechanisms. Dermatologists are more likely to view the medicine as meaningfully differentiated when deeper lesion responses are accompanied by improvements patients can feel.
The limitation is that patient-reported outcomes are vulnerable to expectation and treatment persistence. Patients who remain in a long trial may represent those receiving benefit or tolerating treatment well, while those with limited response may be more likely to discontinue.
MoonLake reported that approximately 90% of eligible participants entered the two-year open-label extension. This supports acceptance and tolerability, but longer follow-up will determine whether the improvement persists and whether treatment discontinuation increases after commercial use.
What the VELA-TEEN results could add to the proposed United States label
MoonLake also reported interim data from 22 adolescents enrolled in VELA-TEEN. Approximately 68% achieved HiSCR75 by week 24, around 45% achieved HiSCR100 and no new safety signals were identified.
The adolescent programme is strategically significant because hidradenitis suppurativa often begins around puberty or early adulthood. Delayed diagnosis and treatment may allow inflammatory lesions to progress into permanent tunnels and scar tissue.
An indication covering patients aged 12 years and older could allow earlier intervention before years of structural damage accumulate. It would also give sonelokimab a broader initial market and place it directly against secukinumab, which already has an adolescent authorisation.
The dataset remains small and comes from an open-label, single-arm study. It is designed primarily to assess pharmacokinetics, safety and tolerability rather than demonstrate comparative efficacy. Strong response percentages should therefore be viewed as supportive rather than independently pivotal.
MoonLake plans to include the adolescent evidence in its biologics licence application. The Food and Drug Administration will determine whether the pharmacokinetic and safety package is sufficient to support a label including younger patients.
An adolescent indication would improve the commercial launch narrative, but it would also increase the importance of long-term safety. Young patients could remain on therapy for many years, making infection, inflammatory bowel disease, immunogenicity and cumulative immune effects especially relevant.
Why the absence of new safety signals is reassuring but not yet a decisive advantage
MoonLake reported no new safety signals through week 52, with the profile remaining consistent with earlier sonelokimab studies. This supports the feasibility of chronic treatment and reduces concern that deeper IL-17A and IL-17F inhibition produces unexpected toxicity over time.
The safety issues associated with IL-17 inhibition are already familiar to dermatologists and rheumatologists. Clinicians monitor for infections, candidiasis and the possibility of inflammatory bowel disease worsening or emerging.
Sonelokimab must demonstrate that its tissue-penetration and dual-cytokine strategy do not increase these risks materially. A smaller antibody-derived molecule may improve delivery into inflamed tissue, but greater tissue exposure could theoretically influence local or systemic immune effects.
The VELA programme provides a substantial safety database, yet uncommon events may become visible only after thousands of patients are treated. Regulatory approval would therefore be followed by continued pharmacovigilance and potentially additional studies.
Safety differentiation may be difficult because established competitors have accumulated larger real-world databases. MoonLake’s nearer-term objective is likely to show that enhanced efficacy does not require a meaningfully worse risk profile.
Commercial advantage would become stronger if post-launch evidence eventually demonstrated lower discontinuation, fewer problematic fungal infections or better tolerability than other dual IL-17 inhibitors. The current dataset supports consistency rather than confirmed superiority.
What MoonLake’s September BLA plan says about the remaining regulatory risk
MoonLake plans to submit the biologics licence application by the end of September 2026 after completing its final pre-submission meeting with the Food and Drug Administration. The company does not expect another formal regulatory meeting before filing.
This timeline suggests that the agency has not required another adult efficacy trial before submission. That reduces the immediate clinical-development risk and allows the review process to begin using VELA-1, VELA-2, VELA-TEEN and supporting Phase 2 evidence.
MoonLake intends to request Priority Review. The company believes the depth of response and adolescent dataset could justify a shorter review period, although the regulator may conclude that existing approved therapies reduce the need for accelerated handling.
Without Priority Review, MoonLake expects a possible United States launch during the third or fourth quarter of 2027. A shorter review could move commercial entry forward by approximately one quarter.
The filing will be an important validation point, but acceptance for review is not approval. Regulators will examine manufacturing, comparability, device presentation, immunogenicity, safety and the statistical interpretation of VELA-2.
Labelling will matter almost as much as approval. Inclusion of adolescents, high-threshold response data, pain outcomes or inflammatory-remission information could strengthen differentiation. A conventional adult-only label focused narrowly on the primary endpoint would leave MoonLake relying more heavily on commercial messaging and medical education.
Can MoonLake finance a launch without creating another major dilution overhang?
MoonLake held approximately $357.9 million in cash, cash equivalents and short-term marketable securities at the end of March 2026. The company expects its existing resources to fund operations through the end of 2027.
That runway covers the planned biologics licence application, regulatory review and much of the expected pre-launch period. MoonLake also has access to a debt facility providing up to $400 million, although borrowing would introduce interest costs and financial obligations.
The company remains pre-revenue and recorded a first-quarter net loss of approximately $69.7 million. Spending is likely to remain elevated as MoonLake completes clinical programmes, expands manufacturing, prepares inventory and builds commercial capabilities.
A launch in hidradenitis suppurativa would require a specialist sales organisation, medical-affairs infrastructure, payer contracting, patient support and distribution. MoonLake could fund these activities independently, seek a commercial partner or become an acquisition target.
The existing cash position reduces immediate financing pressure, but it does not remove dilution risk. A delay in regulatory review, slower launch or additional large Phase 3 programmes could require more capital.
Investors should also consider the cost of developing sonelokimab in psoriatic arthritis and other indications. Portfolio expansion increases potential value but competes with launch preparation for the same financial resources.
What MLTX stock performance reveals about expectations after the 2025 collapse
MoonLake shares closed at approximately $19.21 before the new one-year results, giving the company a market capitalisation near $1.4 billion. The stock gained around 2.8% over five sessions and 5.6% over one month.
The shares remain approximately 69% below their 52-week high of $62.75, reflecting the lasting valuation damage created by the original VELA readout. They are also more than three times above the 52-week low of $5.95, indicating that regulatory alignment and subsequent clinical updates have restored part of the lost confidence.
This creates an unusual investment setup. MoonLake has a Phase 3 asset approaching regulatory submission, a substantial cash position and a potentially large market, yet the valuation remains heavily discounted relative to the expectations held before the week-16 results.
Bullish investors may view the 52-week dataset as evidence that the market overreacted to a statistical issue that did not reflect the medicine’s true long-term performance. Skeptical investors may argue that competitors are already approved, cross-trial comparisons are unreliable and the launch must overcome established payer and physician relationships.
The June 22 investor event could increase volatility by providing more detail on commercial strategy, the proposed label and upcoming psoriatic arthritis catalysts. Retail-investor discussion is likely to focus on whether the latest data justify a return toward the former valuation range.
A rapid recovery is not guaranteed. The stock’s previous high incorporated expectations of two clean Phase 3 wins and clear best-in-class differentiation. Rebuilding that valuation requires regulatory progress, commercial evidence and possibly success in another major indication.
Why the upcoming psoriatic arthritis data could reshape the broader platform value
Hidradenitis suppurativa is the nearest regulatory opportunity, but sonelokimab is also being evaluated in two Phase 3 psoriatic arthritis trials. The IZAR-1 study is expected to report its primary endpoint around mid-2026, followed by IZAR-2 during the second half.
Positive psoriatic arthritis results could transform sonelokimab from a single-market dermatology asset into a broader immunology franchise. Rheumatology expansion would create another large commercial opportunity and improve utilisation of the same manufacturing and sales infrastructure.
The psoriatic arthritis programme carries separate risk. Results in skin disease cannot guarantee strong control of joint inflammation, radiographic progression or multidomain manifestations such as enthesitis and dactylitis.
IZAR-2 includes risankizumab as an active reference, increasing the strategic relevance of the readout. Strong performance could help MoonLake argue that the molecule competes not only with other IL-17 inhibitors but with leading interleukin-23 therapies.
Weak results would narrow the franchise and place more pressure on hidradenitis suppurativa commercialisation. Investors are therefore valuing several catalysts at once, not simply the September filing.
Can durable responses convert sonelokimab into a commercial leader?
The one-year VELA data materially strengthen MoonLake’s regulatory and clinical position. The consistency between trials, deeper responses over time, placebo-crossover effect and patient-reported improvements support genuine and durable biological activity.
The programme still lacks a direct head-to-head trial proving superiority over bimekizumab, secukinumab or adalimumab. MoonLake’s best-in-class claim remains an inference based on separate studies rather than a confirmed comparative result.
Commercial success will depend on whether dermatologists see enough additional value in deeper response, monthly dosing and adolescent use to change prescribing behaviour. Payers may require step therapy through established and potentially discounted biologics before covering another premium product.
MoonLake’s opportunity is nevertheless credible. Hidradenitis suppurativa remains undertreated, many patients respond incompletely to existing therapy and irreversible tissue damage creates a need for stronger early disease control.
The stock’s depressed valuation provides a reason the story may attract renewed attention on Stocktwits and other retail-investor platforms. The same discount also reflects legitimate uncertainty around launch execution, competition and the regulatory interpretation of mixed early Phase 3 statistics.
Sonelokimab has moved beyond the question of whether it works. MoonLake must now prove that the depth and durability of its effect are strong enough to win approval, reimbursement and meaningful market share in an increasingly competitive hidradenitis suppurativa field.
